Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Anti-VEGF/Immunotherapy Combinations in Kidney Cancer

July 17th 2017

New Strategies in Kidney Cancer

July 17th 2017

Immunotherapy in Kidney Cancer

July 17th 2017

Practical Experience With Lenvatinib/Everolimus in RCC

July 17th 2017

mTOR/TKI Combination Therapy in Kidney Cancer

July 17th 2017

Role of mTOR Inhibition in Kidney Cancer

July 17th 2017

Frontline TKI Strategies in Kidney Cancer

July 17th 2017

Kidney Cancer: Continuing to Improve Survival

July 17th 2017

Understanding the Biology of Kidney Cancer

July 17th 2017

Unmet Needs in CINV

July 17th 2017

Use of Dexamethasone in CINV

July 17th 2017

Use of Olanzapine in CINV

July 17th 2017

5-HT3/NK1 Receptor Antagonist Combinations for CINV

July 17th 2017

Role of NK1 Receptor Antagonists in Treating CINV

July 17th 2017

Role of 5-HT3 Receptor Antagonists in Treating CINV

July 17th 2017

Treating CINV Due to Immunotherapy and Targeted Therapy

July 17th 2017

Patient Education Materials for CINV

July 17th 2017

Patient Risk Factors in CINV

July 17th 2017

Multidisciplinary Approach to Treating CINV

July 17th 2017

Classification of Emetogenicity of Chemotherapeutic Agents

July 17th 2017